A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Clinical trial NCT06615479 · RECRUITING
Trial details
- NCT number
- NCT06615479
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-12
- Primary completion
- 2027-12-30
- Enrollment
- 440
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.